ImmunologybioRxiv
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile
DOI 10.1016/j.xcrm.2023.100955
Author
V. Martel-Laferriere
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2021-2022 · peak 5/yrCo-Author Collaboration Network
10 top collaborators · 45 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship7 papers
Recent·Most cited
- ImmunologybioRxivPreprint
A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity
A. Nicolas, G. Sannier, M. Dube…·D. E. Kaufmann
This study shows that a longer interval between SARS-CoV-2 mRNA vaccine doses enhances B cell responses but has minimal impact on T cell immunity.
DOI 10.1101/2022.08.03.502672 - MicrobiologybioRxiv
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses
D. Chatterjee, A. Tauzin, L. Marchitto…·A. Finzi
This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.
DOI 10.1016/j.celrep.2022.110429 - ImmunologybioRxiv
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
M. Nayrac, M. Dube, G. Sannier…·D. E. Kaufmann
The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.
DOI 10.1016/j.celrep.2022.111013 - ImmunologybioRxiv
Covid-19 vaccine immunogenicity in people living with HIV-1
L. Nault, L. Marchitto, G. Goyette…·C. Tremblay
This study evaluates mRNA vaccine immunogenicity in HIV-positive individuals, finding similar anti-RBD IgG responses to controls in those with CD4 counts >250 cells/mm3, but significantly lower responses in those with <250 cells/mm3.
DOI 10.1016/j.vaccine.2022.04.090 - ImmunologybioRxivPreprint
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
A. Tauzin, M. Nayrac, M. Benlarbi…·A. Finzi
This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.
DOI 10.1101/2021.03.18.435972 - MicrobiologybioRxiv
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
S. P. Anand, J. Prevost, M. Nayrac…·A. Finzi
This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.
DOI 10.1016/j.xcrm.2021.100290